Imexpharm

What Imexpharm does

Imexpharm (Công ty Cổ phần Dược phẩm Imexpharm) is a Vietnamese pharmaceutical manufacturer, formulator, and distributor founded in 1977 and headquartered in Cao Lãnh City, Dong Thap Province, Vietnam. The company operates four manufacturing clusters—three certified to EU-GMP and one to WHO-GMP standards—with twelve EU-GMP production lines supporting a portfolio of more than 14 therapeutic categories. Its product range spans injectable and oral antibiotics (the company's flagship franchise, including first generic antibiotics on EU-GMP lines), cardiovascular, musculoskeletal, respiratory, antihistamine, digestive/hepatobiliary, diabetes, antiparasitic, ophthalmology, topical, vitamins and minerals, and health supplements. Notable technical capabilities include proprietary enzymatic technology for antibiotic raw material processing and pioneer production of colistin in powder form for inhalation solutions, used in severe drug-resistant infection treatment.

The company employs more than 1,400 people and distributes through 20 sales branches and offices covering all regions of Vietnam, reaching pharmacies, hospitals, and healthcare providers via a direct sales-led model. Its go-to-market combines field sales with scientific seminars and medical conference partnerships (e.g., HCM City Respiratory Society Annual Congress 2026, the 42nd Annual ENT Scientific Conference). R&D investment of approximately 5% of annual revenue supports more than 100 active research projects and the launch of 10-20 new products per year. As of May 2026, the company is controlled by China's Livzon Group (one of the top-25 Chinese pharmaceutical firms), which acquired a 67.87% stake for $221M, replacing SK Group as the controlling shareholder and adding U.S. FDA-certified API capabilities to Imexpharm's platform.

Imexpharm generates revenue through one-time sales of manufactured pharmaceutical products across its therapeutic categories, with a primarily domestic Vietnamese customer base supplemented by 28 product registrations for 11 products in European markets. The company is publicly listed on the Vietnam stock exchange under ticker IMP.VN, maintains investor relations functions in Ho Chi Minh City, and has received multiple industry recognitions including Top 1 Best Workplace in Vietnam 2025 in the pharmaceutical/medical device sector and 6 consecutive years on the Top 50 Most Efficient Business Companies in Vietnam list.

Name

Imexpharm

Legal name

Công ty Cổ phần Dược phẩm Imexpharm

Website

https://imexpharm.com

Company type

Public

Founded year

1977

Operating status

Operating

Headcount range

11–50 employees

Short description

Imexpharm is a Vietnamese pharmaceutical manufacturer and distributor, operating 4 GMP-certified production facilities and 20 sales branches serving pharmacies and hospitals across Vietnam with a 14-category product portfolio led by antibiotics, cardiovascular, and respiratory medications.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

Keywords

• Pharmaceutical manufacturing
• Generic antibiotics
• EU-GMP production
• Pharmaceutical distribution
• Therapeutic drugs

Headquarters

HQ city

Hai Phong

HQ country

Vietnam

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Manufacturing and Distribution: Imexpharm generates revenue through manufacturing and distributing pharmaceutical products including antibiotics, cardiovascular drugs, musculoskeletal treatments, respiratory medications, and other therapeutic categories. The company operates 12 EU-GMP certified production lines.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Imexpharm manufactures, processes, trades, imports, and exports pharmaceutical products across 14+ therapeutic categories including injectable and oral antibiotics, cardiovascular, musculoskeletal, respiratory, antihistamine, digestive/hepatobiliary, diabetes, antiparasitic, ophthalmology, topical, vitamins and minerals, and health supplements. The company operates 4 manufacturing clusters (3 EU-GMP and 1 WHO-GMP certified) with 12 EU-GMP production lines, distributing its products through 20 sales branches to hospitals, pharmacies, and healthcare providers across Vietnam.

Product overview

Imexpharm is a Vietnamese pharmaceutical company operating as a diversified drug manufacturer and distributor with 14 product categories spanning therapeutic areas including injectable and oral antibiotics (the company's strongest portfolio, including first generic antibiotics on EU-GMP lines), cardiovascular, musculoskeletal (with a new ibuprofen product launched in May 2026), respiratory, antihistamine, digestive/hepatobiliary, diabetes, antiparasitic, topical, and vitamins/supplements. The company operates 4 manufacturing clusters (3 EU-GMP certified, 1 WHO-GMP certified) with 12 EU-GMP production lines, maintaining 100+ research projects annually and launching 10-20 new products each year. The portfolio is organized by therapeutic categories, with particular strength in antibiotics and respiratory medications.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 28 product registrations for 11 products in Europe
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered minor and core.

• SandozminorStrategic or Co-development PartnerSandoz logo appears in the partners section of Imexpharm's website, indicating a partnership or collaboration in the pharmaceutical sector.
• HCM City Respiratory SocietycoreStrategic or Co-development PartnerImexpharm partnered with HCM City Respiratory Society for the Annual Congress 2026 (HRS 2026), which attracted over 500 in-person and 1,500 online participants, reinforcing the company's commitment to respiratory disease treatment quality.
• 42nd Annual ENT Scientific ConferencecoreStrategic or Co-development PartnerImexpharm partnered with the 42nd Annual Ear Nose Throat Scientific Conference in Nha Trang, gathering nearly 700 experts and physicians to share treatment solutions aligned with real-world needs.
• Hồ Xuân Hương Lake Cherry Blossom ProjectminorOthersImexpharm collaborated with Lâm Đồng Young Entrepreneurs Association on the 'Thousand Cherry Blossom Trees - For a Forever Pink Đà Lạt' project, planting 50 new trees at Hồ Xuân Hương area to promote environmental sustainability.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• DHG Pharmaceutical JSC (Hau Giang Pharma): Vietnam's largest domestic pharmaceutical manufacturer, producing branded generics across cardiovascular, antibiotics, and OTC categories. Closely comparable to Imexpharm in therapeutic mix, EU-GMP-style manufacturing ambitions, and nationwide pharmacy/hospital distribution.
• Traphaco JSC: Leading Vietnamese pharma combining traditional herbal medicine and Western generics with a national distribution network. Comparable to Imexpharm as a listed Vietnamese pharma manufacturer targeting hospitals and retail pharmacies.
• Pymepharco JSC: Vietnamese generic pharmaceutical manufacturer with EU-GMP facilities and a broad therapeutic portfolio. Directly comparable to Imexpharm on manufacturing standards, generic product breadth, and hospital-channel go-to-market.
• Bidiphar JSC (Binh Dinh Pharmaceutical & Medical): Vietnamese pharma manufacturer with WHO-GMP certified production and a diverse generic portfolio. Comparable to Imexpharm in scale, GMP manufacturing footprint, and domestic hospital/pharmacy distribution.
• Domesco Medical Import Export JSC: Vietnamese pharma manufacturer focused on generic prescription drugs, OTC, and functional foods with nationwide distribution. Comparable to Imexpharm in product breadth and B2B sales motion through pharmacies and hospitals.

Regional players

• Agimexpharm JSC: Vietnamese pharma manufacturer and Imexpharm's listed partner. Comparable as a domestic peer with overlapping generic portfolio and shared distribution ecosystem in southern Vietnam.
• Hovid Berhad: Malaysian generic pharmaceutical manufacturer with export reach across ASEAN. Comparable to Imexpharm in generic manufacturing, regional export ambitions, and therapeutic breadth including antibiotics and OTC.
• Yuyu Pharma (Korea Yuyu Co., Ltd.): Korean pharma manufacturer with established generics, OTC, and health-supplement portfolio in Vietnam and Southeast Asia. Comparable to Imexpharm as a foreign-affiliated generics manufacturer operating in the Vietnam market.

Broad incumbents

• Sandoz (Novartis): Global leader in off-patent generics and biosimilars, operating broadly in Vietnam. Comparable to Imexpharm as a high-volume generics competitor across many of the same therapeutic categories; also a listed Imexpharm partner.
• Sanofi Vietnam: Multinational pharmaceutical incumbent with broad prescription and consumer health presence in Vietnam. Comparable as a larger player overlapping with Imexpharm across cardiovascular, respiratory, and OTC categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/ImexpharmCorporation
• LinkedInlinkedin.com/company/imexpharm-corporation

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imexpharm